Insilico Medicine announces novel 3CL protease inhibitor preclinical candidate for COVID-19 treatment
NEW YORK, May 24, 2022 --- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of ...